XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces attendance and presentation at the Microcap Conference hosted by DealFlow Events on January 28 through 30, 2025 in Atlantic City, NJ.
Attendance at this conference continues outreach to the investment community and provides XORTX with an opportunity to update investors on our newly announced gout program.
The presentation on January 29, 2025 will review the Company’s plans to advance the XRx-026 program for gout through a New Drug Application (“NDA”) filing, and activities associated with the XRx-008 program for autosomal dominant polycystic kidney disease (“ADPKD”), including registration clinical trial preparations.
Dr. Allen Davidoff, XORTX CEO stated, “This conference is designed to give participants one-on-one meetings with new investors as well as the opportunity to present a Company overview to all of the conference attendees. We are excited to be able to reach out to the quality investors who will attend this conference and to elaborate on our exciting plans for bringing our gout program in the near term, and ADPKD programs in the longer term, through to FDA marketing approval.”
XORTX’s presentation will be recorded and available after the conference on the Company’s website.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; 2) our XRx-026 program for the treatment of allopurinol intolerant gout; and 3) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection.
In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
At XORTX, we are dedicated to developing medications to improve the quality of life and health of kidney disease patients and individuals with gout. Additional information on XORTX is available at www.xortx.com.
care of the redaction
please follow us also with a like on Instagram, user name: gio.vanni.acerbi
